1.33% volatility in Astrazeneca plc ADR (AZN) last month: This is a red flag warning

On Monday, Astrazeneca plc ADR (NASDAQ: AZN) was -1.37% down from the session before settling in for the closing price of $62.26. A 52-week range for AZN has been $61.70 – $76.56.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Annual sales at Healthcare sector company grew by 16.24% over the past five years. When this article was written, the company’s average yearly earnings per share was at 13.48%. With a float of $3.10 billion, this company’s outstanding shares have now reached $3.10 billion.

Let’s look at the performance matrix of the company that is accounted for Aug 10 2023 employees.

Astrazeneca plc ADR (AZN) Insider Updates

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Astrazeneca plc ADR stocks. The insider ownership of Astrazeneca plc ADR is 0.05%, while institutional ownership is 16.01%.

Astrazeneca plc ADR (AZN) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of 61.41 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 13.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.10% during the next five years compared to 17.72% growth over the previous five years of trading.

Astrazeneca plc ADR (NASDAQ: AZN) Trading Performance Indicators

You can see what Astrazeneca plc ADR (AZN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.16. Likewise, its price to free cash flow for the trailing twelve months is 20.54.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.91, a number that is poised to hit 0.97 in the next quarter and is forecasted to reach 4.69 in one year’s time.

Technical Analysis of Astrazeneca plc ADR (AZN)

Astrazeneca plc ADR (NASDAQ: AZN) saw its 5-day average volume 13.38 million, a positive change from its year-to-date volume of 7.18 million. As of the previous 9 days, the stock’s Stochastic %D was 17.19%. Additionally, its Average True Range was 1.30.

During the past 100 days, Astrazeneca plc ADR’s (AZN) raw stochastic average was set at 8.98%, which indicates a significant decrease from 12.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.41% in the past 14 days, which was higher than the 21.54% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $66.26, while its 200-day Moving Average is $68.25. Nevertheless, the first resistance level for the watch stands at $61.74 in the near term. At $62.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $62.71. If the price goes on to break the first support level at $60.77, it is likely to go to the next support level at $60.14. Assuming the price breaks the second support level, the third support level stands at $59.80.

Astrazeneca plc ADR (NASDAQ: AZN) Key Stats

There are 3,100,325K outstanding shares of the company, which has a market capitalization of 190.39 billion. As of now, sales total 44,351 M while income totals 3,288 M. Its latest quarter income was 11,492 M while its last quarter net income were 1,374 M.